Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound ...

"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Ro announced earlier that it is working with Eli Lilly (LLY) and Company to streamline access to Zepbound single-dose vials for Ro patients ...

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...

We recently published a list of Jim Cramer’s Latest Calls: Top 10 Stocks. In this article, we are going to take a look at ...

Eli Lily continues to dominate the weight loss market, willing to crush any competitor that threatens its dominance.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...